SEC Form 4 · accession 0001209191-18-060814
AERIE PHARMACEUTICALS INC · AERI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Casey C. Kopczynski
Officer — Chief Scientific Officer
Period of report
Dec 3, 2018
Accepted (ET)
Dec 4, 2018 · 4:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001337553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Dec 3, 2018 | S | 10,701 | $39.7879 | D | 118,042 | D | |
| Common StockF2,F4 | Dec 3, 2018 | S | 299 | $40.5464 | D | 117,743 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These sales were made pursuant to the reporting person's Rule 10b5-1 plan.
- F2The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4 to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions pursuant to the reporting person's Rule 10b5-1 plan at prices ranging from $39.50 to $40.36, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions pursuant to the reporting person's Rule 10b5-1 plan at prices ranging from $40.54 to $40.62, inclusive.